For the quarter ending 2026-03-31, GOSS made $16,955K in revenue. -$45,539K in net income. Net profit margin of -268.59%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 16,955 | 13,799 | 13,294 | 11,489 |
| Research and development | 43,075 | 48,935 | 45,542 | 41,575 |
| In process research and development | - | -1 | 7,476 | - |
| General and administrative | 18,746 | 10,904 | 9,390 | 8,679 |
| Total operating expenses | 61,821 | 59,838 | 62,408 | 50,254 |
| Loss from operations | -44,866 | -46,039 | -49,114 | -38,765 |
| Interest income | 354 | 447 | 687 | 542 |
| Interest expense | 2,755 | 2,751 | 2,748 | 2,744 |
| Other income, net | 603 | 1,017 | 2,954 | 2,694 |
| Total other income (gain), net | -1,798 | -1,287 | 893 | 492 |
| Loss before provision (benefit) for income taxes | - | -47,326* | -48,221 | -38,273 |
| Provision (benefit) for income taxes | - | -88* | 0 | 0 |
| Net loss | -46,664 | -47,238 | -48,221 | -38,273 |
| Foreign currency translation | 1,192 | -20 | -130 | -4,195 |
| Unrealized loss on marketable securities | -67 | -22 | 111 | -69 |
| Other comprehensive income (loss) | 1,125 | -42 | -19 | -4,264 |
| Comprehensive loss | -45,539 | -47,280 | -48,240 | -42,537 |
| Basic EPS | -0.2 | -0.204 | -0.21 | -0.17 |
| Diluted EPS | -0.2 | -0.204 | -0.21 | -0.17 |
| Basic Average Shares | 234,137,364 | 232,001,528 | 227,981,475 | 227,275,466 |
| Diluted Average Shares | 234,137,364 | 232,001,528 | 227,981,475 | 227,275,466 |
Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. (GOSS)